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Abstract 
Astrocyte-neuron interactions protect neurons from iron-mediated toxicity. As dopamine 
can be metabolized to reactive quinones, dopaminergic neurons are susceptible to 
oxidative damage and ferroptosis-like induced cell death. Detoxification enzymes are 
required to protect neurons. Brain-derived neurotrophic factor (BDNF) plays a key role 
in the regulation of redox sensitive transcription factor Nrf2 in astrocytes and metabolic 
cooperation between astrocytes and neurons. This article reviews the importance of 
BDNF and astrocyte-neuron interactions in the protection of neurons against oxidative 
damages in rodent brains. We previously proposed that BDNF activates Nrf2 via the 
truncated TrkB.T1 and p75
NTR
 receptor complex in astrocytes. Stimulation by BDNF 
generates the signaling molecule ceramide, which activates PKCζ leading to induction 
of the CK2-Nrf2 signaling axis. As a cell clock regulates p75
NTR
 expression, we 
suggested that BDNF effectively activates Nrf2 in astrocytes during the rest phase. In 
contrast, neurons express both TrkB.FL and TrkB.T1, and TrkB.FL tyrosine kinase 
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activity inhibits p75
NTR
-dependent ceramide generation and internalizes p75
NTR
. 
Therefore, BDNF may not effectively activate Nrf2 in neurons. Notably, neurons only 
weakly activate detoxification and antioxidant enzymes/proteins via the Nrf2-ARE 
signaling axis. Thus, astrocytes may provide relevant transcripts and/or proteins to 
neurons via microparticles/exosomes increasing neuronal resistance to oxidative stress. 
Circadian increases in the levels of circulating glucocorticoids may further facilitate 
material transfer from astrocytes to neurons via the stimulation of pannexin 1 
channels-P2X7R signaling pathway in astrocytes at the beginning of the active phase. 
Dysregulation of astrocyte-neuron interactions could therefore contribute to the 
pathogenesis of neurodegenerative diseases including Parkinson’s disease. 
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1. Introduction 
Ferroptosis is defined as a form of cell death characterized by iron-dependent 
accumulation of lipid hydroperoxides to lethal levels. Aberrations in brain iron 
homeostasis have been implicated in pathological cell death associated with various 
diseases including neurodegenerative diseases such as Parkinson’s and Alzheimer’s 
diseases (reviewed in [1-3]). Iron plays a fundamental role in the development of the 
central nervous system as well as in several neuronal functions including synaptic 
plasticity [4]. Astrocytes have been demonstrated to serve critical functions in the 
protection of neurons from iron overload. Non-transferrin-bound iron is taken up via 
resident transient receptor potential channels in quiescent astrocytes and the de novo 
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expressed divalent metal transporter 1 in activated astrocytes [5-7]. Astrocytes through 
these routes accumulate iron and various iron-containing compounds, store iron 
efficiently in ferritin and also export iron (reviwed in [4,8,9]). Notably, serum iron 
levels and expression of divalent metal transporter 1, transferrin receptor and other iron 
related gene expression in tissues exhibit diurnal variation [10]. 
Parkinson’s disease is caused by neuronal loss in multiple brain regions, especially 
dopaminergic neurons in the substantia nigra pars compacta. Although it is difficult to 
pinpoint the type of neuronal death involved [11], biochemically, Parkinson’s disease is 
characterized by mitochondrial dysfunction, accumulation of iron, diminished copper 
content and depleted glutathione (GSH) levels in these regions [12,13]. These 
symptoms suggest the existence of iron dyshomeostasis and iron-mediated oxidative 
damage. Preventing neuronal death is a major strategy for disease-modifying therapies, 
but it is currently unknown what causes iron overload and the defects in detoxification 
systems in the disease (reviewed in [14,15]).  
As dopamine metabolism produces reactive o-quinones, dopaminergic neurons are 
especially susceptible to oxidative stress and mitochondrial dysfunction [16]. Tyrosine 
hydroxylase is the rate-limiting enzyme in dopamine synthesis from tyrosine. In 
neurons, a part of dopamine is oxidized to dopamine ο-quinone and then metabolized to 
generate aminochrome, which causes neurotoxicity [16]. Notably, some quinones 
including 9,10-phenanthraquinone are highly toxic inducing ferroptosis-like cell death 
[17]. Therefore, removal of aminochrome is essential for the protection of neurons. 
Glutathione S-transferase mu 2 (GSTM2) plays a key role in detoxifying o-quinones 
[16]. Aminochrome is further metabolized by NAD(P)H quinone oxidoreductase 
(NQO1/DT-diaphorase) leading to the formation of neuromelanin, which chelates iron 
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and other metals [18] protecting neurons from oxidative stress (Fig. 1 A). As the 
contents of ferritins are low in neurons, neuromelanin is the major iron storage in 
substantia nigra neurons in normal individuals [19]. Notably, iron is required for the 
dynamics of striatal dopamine, as low substantia nigra iron is a known pathology of 
Restless Legs Syndrome, which accompanies increases in extracellular striatal 
dopamine due to a defect in a dopamine receptor 2 mediated feedback inhibition of 
dopamine release [20]. 
Synthesis of the iron-containing prosthetic group-heme and iron-sulfur clusters 
occurs in mitochondria. Mitochondria generate reactive oxygen species as byproducts of 
molecular oxygen consumption in the electron transport chain. Superoxide anion and 
hydrogen peroxide produced in mitochondria are precursors of hydroxyl radical through 
the participation of transition metals [21,22]. Glutathione (GSH) and GSH-dependent 
detoxification enzymes play a major role in the elimination of the hydroperoxides in 
mitochondria as well as in the cytoplasm. GSH is synthesized in the cytoplasm and 
sequestered in mitochondria by the action of a membrane carrier that transports GSH 
into mitochondrial matrix [23]. The intracellular cysteine pool limits the synthesis of 
GSH. Astrocytes induce cystine transport activity to maintain intracellular GSH levels 
in culture [24]. In contrast, neurons do not express cystine transport activity and depend 
on cysteine transport for the synthesis and maintenance of intracellular GSH levels [24, 
25]. 
To adapt to oxidative stress conditions, cells activate the transcription factor nuclear 
factor-E2-related factor 2 (Nrf2) which regulates the expression of a large number of 
genes, including detoxification enzymes, antioxidant proteins and GSH related genes 
via the antioxidant responsive element (ARE) in a cell type specific manner [26-28]. As 
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the brain consumes glucose and oxygen at high rates, dysregulation of the Nrf2-ARE 
defense system is associated with oxidative damage and ultimately neurodegeneration. 
Activation of Nrf2 in mouse brain astrocytes protect cells from cytotoxicity induced by 
iron overload [29]. Recent studies have identified that several genes involved in heme 
synthesis, hemoglobin catabolism, iron storage, and iron export are under the control of 
Nrf2 [30].  
Brain-derived neurotrophic factor (BDNF) is the major neurotrophin expressed in 
adult brain and has been implicated in regulating neuronal survival, differentiation, and 
synaptic plasticity. We recently proposed that BDNF plays a key role in circadian 
activation of Nrf2 in astrocytes and suggested that BDNF activates Nrf2 via receptor 
combination of the truncated form of TrkB.T1 and the low affinity receptor p75
NTR
, 
which generate the lipid signal mediator ceramide upon stimulation [31]. As p75
NTR
 
expression is directly controlled by the cell clock core transcription factor complex 
Clock-Bmal1, we thought activation of Nrf2 via BDNF depends on circadian rhythm 
[28]. BDNF plays a key role in the maintenance of dopaminergic neurons in the 
substantia nigra pars compacta in mice [32], but how BDNF protects neurons is not 
fully elucidated. 
In this review, we discuss the importance of circadian rhythm in BDNF-mediated 
metabolic cooperation between astrocytes and neurons, and the role of Nrf2 activation 
in astrocytes in the protection of neurons against ferroptosis-like cell death (Fig. 1 B). 
As neurons express both full-length and truncated forms of TrkB, TrkB.FL and TrkB.T1, 
the signaling pathways regulated by BDNF are much more complicated compared to 
those in astrocytes. Another neuron-specific feature is that the Nrf2-ARE signaling axis 
upregulates a totally different set of genes compared to astrocytes. Although activation 
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of the Nrf2-ARE axis upregulates classical detoxification and antioxidant 
enzymes/proteins in astrocytes, neurons hardly express these genes upon Nrf2 activation, 
rendering neurons highly susceptible to oxidative damages (Table 1) [33]. These 
differences between neurons and astrocytes raise questions as to whether BDNF plays a 
role in Nrf2 activation in neurons and how neurons are protected against oxidative stress 
without the ability to upregulate expression of key cellular antioxidants?  
 
2. GSH-dependent protection of brain cells  
Ferroptosis can easily be induced in cultured cells by depleting cellular GSH. Bannai 
et al. [34] first observed this phenomenon in human diploid fibroblasts cultured in a 
medium deficient in cystine. Elegant studies by Bannai and colleagues revealed that 
cellular GSH readily effluxes from fibroblasts, with synthesis of GSH from precursor 
amino acids required to maintain intracellular GSH levels and the cysteine pool limiting 
GSH synthesis. These researchers identified a membrane transport system highly 
specific for cystine and glutamate [35], which plays a key role in the maintenance of 
cellular cysteine and GSH in cultured fibroblasts (reviewed in [25,36]). Cystine 
transport activity was termed system xc- and is induced in many cell types including 
fibroblasts, macrophages and astrocytes during culture in vitro. However, other cells 
such as neurons and lymphocytes can hardly induce cystine transport activity in 
response to oxidative stress. The latter cells depend on cysteine uptake for maintenance 
of cellular GSH and can only survive in standard culture media when co-cultured with 
system xc- expressing cells, known to secrete and provide cysteine to recipient cells 
[24,25].  
The expression of the cystine transporter (xCT), a component of cystine-glutamate 
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exchange system xc-, is observed in some specific regions of the adult brain [37,38]. 
Notably, a subpopulation of astrocytes are labeled with an xCT antibody, but with 
greatly varying intensities [39]. However, deficiency of xCT in mice is associated with 
no apparent problems under standard breeding conditions [37,38]. Notably, plasma 
levels of cystine are higher in xCT deficient mice compared to normal mice, but other 
amino acids including cysteine, glycine and glutamate are similar between xCT 
deficient and wild type mice. These results suggest that deficiency in cystine transport 
activity itself does not cause GSH depletion in cells and tissues in mice under normal 
conditions [38].  
Nrf2 positively regulates the activity of system xc- or gene expression of xCT in 
cultured macrophages and other cells types [25,40]. Activating transcription factor 4 
(ATF4), which is increased in response to a diverse array of microenvironmental 
stresses, including amino acid depletion and endoplasmic reticulum stress, also 
regulates xCT gene expression [41]. Notably, an increase in the cystine/glutamate 
exchanger in astrocytes does not always protect co-cultured neurons, as enhanced 
glutamate efflux may cause excitotoxicity in neurons. Liu et al. [42] observed that 
fibroblast growth factor-2 (FGF-2) upregulates system xc- activity in astrocytes with 
increased glutamate release causing AMPA/kainate receptor mediated toxicity. As 
FGF-2 can activate ATF4 [43,44], the effect of FGF-2 on upregulation of system xc- 
activity may partly depend on ATF4. Notably, the protein level of ATF4 is upregulated 
in both Alzheimer’s disease patients and the disease model in mouse brain [45]. In 
contrast to ATF4, Nrf2 protects neurons from kainite toxicity, highlighting the 
importance of the Nrf2-ARE dependent detoxification system in addition to GSH for 
the protection of neurons from glutamate excitotoxicity [46].  
10 
 
GSH transferases (GSTs) play important roles in eliminating toxic metabolites. 
GSTM2 has much higher activity than other GSTs in catalyzing the GSH conjugation of 
aminochrome and its precursor dopamine ο-quinone [47] (Fig. 1 A). GSTM2 is 
expressed in astrocytes but not synthesized in dopaminergic neurons. As astrocytes have 
been shown to provide GSTM2 to neurons to help protect against neurotoxicity of 
aminochrome, this implicates an intercellular communication system mediating transfer 
of cytoplasmic proteins from astrocytes to neurons [16,48]. In addition to GSTs, GSH 
peroxidases (GPxs) reduce phospholipid hydroperoxides and afford protection for 
neurons. GSH peroxidase 4 (GPx4) is a selenoenzyme and long and short isoforms of 
GPx4 are generated from the GPx4 gene. Ferroptosis-associated markers such as 
elevated lipid peroxidation, ERK activation and augmented neuroinflammation, have 
been observed in GPx4 deficient mice brain [49]. Peroxiredoxin 6 is a bifunctional 
enzyme with both GSH peroxidase and acidic Ca
2+
-independent phospholipase A2 
activities [50]. When mitochondrial membranes are damaged by oxidative stress, Prx6 
translocates to depolarized mitochondria from the cytoplasm to limit mitochondrial 
dysfunction and regulate the initial stage of mitophagy [51,52].  
 
3. Nrf2 activates different genes in astrocytes and neurons  
Nrf2 plays a key role in the protection of cells and tissues from oxidative damage via 
upregulation of detoxification enzymes, including GSTs, NQO1, antioxidant enzymes 
such as heme oxygenase-1, peroxiredoxin 1, and cystine transport activity [26,27]. Nrf2 
also regulates expression of iron storage protein ferritin [53]. Recent studies 
demonstrated that administration of Nrf2 activators that cross the blood-brain barrier, 
such as dimethyl fumarate and fumaric acid esters, protect neurons against oxidative 
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damage caused by neurotoxins such as 6-hydroxidopamine and 
1-metyl-4-phenyl-1,2,3,6-tetrahydropyridine, used in animal models of Parkinson’s 
disease [54,55].  
However, it is important to highlight that Nrf2 target genes in neurons are quite 
different from those expressed in astrocytes. Kraft et al. [33] analyzed Nrf2-dependent 
gene expression separately in neurons and astrocytes freshly prepared from mouse 
embryonic brains. These authors treated primary cultured cells with the well-known 
Nrf2 activator tert-butyl-hydroquinone (tBHQ) and found that astrocytes upregulate 
typical Nrf2-dependent genes including detoxification enzymes including GSTs, NQO1, 
ferritin and GSH synthetase in addition to glucose metabolism-related genes (Table 1). 
In contrast, most of these genes are hardly upregulated in neurons by tBHQ [33]. Of the 
97 genes increased in the astrocyte-enriched population, only 4 transcripts 
(glutathione-S-transferase mu1, glucose phosphate isomerase 1, malate NADP 
oxidoreductase and neuroleukin) are also increased in neurons. In neurons, some of the 
upregulated genes are related to mitochondrial activation, calcium binding and transport, 
cell adhesion and integrin signaling and synaptic activity (Table 1). One of the Nrf2 
upregulated genes, mitochondrial creatine kinase, provides a temporal and spatial 
energy buffer to maintain cellular energy homeostasis. Ndufa1 encodes one of the 
proteins composing mitochondrial complex I (the proton-translocating NADH-quinone 
oxidoreductase), exhibiting an essential role for the complex I activity [56]. S100A1 is a 
Ca
2+
-sensing protein of the EF-hand family and interacts with mitochondrial F1-ATPase 
and enhances ATP synthesis [57]. Thus, activation of Nrf2 apparently increases 
mitochondrial activity in neurons, and yet fails to induce classical Nrf2-regulated 
antioxidants and detoxification enzymes. These results raise the question as to how 
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neurons manage to cope with oxidative stress following activation of mitochondria? 
 
4. Neurotrophins can activate Nrf2-ARE signaling axis 
Neurotrophins such as NGF and BDNF play important roles in the survival and 
function of neurons and astrocytes. Previously, Kosaka et al. [58] showed that NGF 
activates Nrf2 in rat pheochromocytomatous PC12 cells, however, the precise 
mechanism of NGF-mediated Nrf2 activation remains to be elucidated. Dobrowsky et al. 
[59] were the first to report that stimulation of the low affinity neurotrophin receptor 
p75
NTR
 activates neutral sphingomyelinase to generate ceramide. Blöchl and Sirrenberg 
[60] measured ceramide generation in rat mesencephalic neurons in culture following 
stimulation either with NGF or BDNF, with NGF generating ceramide levels about 
3-fold higher than control. As neurons express very low levels of TrkA, these authors 
concluded that NGF generated ceramide occurs through direct interaction with p75
NTR
. 
Although high levels of ceramide are toxic, physiologically low levels of ceramide can 
activate atypical protein kinase C ζ (PKCζ) [61]. As PKCζ can activate CK2, we 
proposed that neurotrophins are able to activate p75
NTR
-ceramide-PKCζ-CK2 signaling 
pathway. Subsequently, CK2 directly phosphorylates and stabilizes/activates Nrf2 
[31,62,63] (Fig. 2 A).  
In contrast to NGF, BDNF only marginally increases ceramide under similar culture 
conditions irrespective of the fact that the neurons express full length TrkB (TrkB.FL). 
However, pretreatment of neurons with the tyrosine kinase inhibitor K252a increases 
ceramide generation, suggesting that tyrosine kinase activity of TrkB.FL inhibits 
p75
NTR
-mediated activation of neutral sphingomyelinase [60]. Their study indicates that 
the BDNF-TrkB.FL-p75
NTR
 axis does not induce ceramide-dependent Nrf2 activation in 
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neurons. Their study further suggested that the truncated form of TrkB (TrkB.T1), 
lacking the intracellular receptor tyrosine kinase domain, does not inhibit ceramide 
generation via p75
NTR
 (Fig. 2 A). As astrocytes predominantly express TrkB.T1, we 
proposed that the BDNF-TrkB.T1-p75
NTR
 mediated generation of ceramide triggers the 
PKCζ-CK2-Nrf2 signaling pathway [31].  
However, p75
NTR
 is a clock component and expression is under the direct control of 
the Clock-Bmal1 core transcription factor complex [64]. The Clock-Bmal1 complex 
regulates expression of negative transcriptional regulators, including Cry, Period and 
Rev-erb thereby forming a negative feedback loop. Cry and Period proteins form a 
regulatory complex which inhibits Clock-Bmal1 transactivation of target genes and the 
nuclear receptors Rev-erb α and β are transcriptional repressors and repress BMAL1 
transcription [65,66] (Fig. 2 B). Therefore, the p75
NTR
-mediated signaling pathway 
should change depending on the circadian rhythm in astrocytes. As period 2 (Per2) 
levels are high in the early light/rest phase in local regions of rat brain [67,68] (Fig. 2 B), 
we predicted that the p75
NTR
-Nrf2 signaling pathway also effectively functions in the 
similar time phase [31]. Currently, however, the circadian variation of p75
NTR
 protein in 
brain cells has yet to be investigated. 
Dopamine release in the brain has a daily rhythm peaking during the dark/active 
phase in rodents, which is significantly different from that of Per2 [67] (Fig. 2 B). 
Although the underlying mechanisms for regulation of extracellular dopamine rhythm 
are not known, repression of tyrosine dehydrogenase gene transcription by Rev-erbα 
may partly modulate the dopamine rhythm [69,70]. Thus, dopaminergic neurons should 
be fully protected from toxicity of the dopamine metabolites during the active/dark 
phase. 
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5. Differences in BDNF signaling in astrocytes and neurons 
Circadian rhythm differentially regulates metabolic activity in astrocytes and neurons 
to share oxygen consumption and to effectively utilize glucose and its metabolites. We 
proposed that the BDNF-TrkB.T1-p75
NTR
-ceramide signaling axis activates the 
PKCζ-CK2-Nrf2 pathway mainly in the light/rest phase in rodent astrocytes [31]. 
Notably, CK2 also facilitates protein import into the mitochondrial matrix to enhance 
oxidative phosphorylation [71]. Ceramide also activates protein phosphatase 1 (PP1) 
[72], which plays a key role in glycogen synthesis [73]. Therefore, when neuronal 
activity remains low, astrocytes favorably synthesize glycogen to store energy which 
consumes ATP and requires mitochondrial activity. But in the dark/active phase, when 
neuronal activity increases, astrocytes undergo a metabolic shift towards increasing 
glycogen hydrolysis and glycolysis to produce lactate as a substrate for the TCA cycle 
in neurons. This phase change can occur simultaneously with the down-regulation of 
p75
NTR
 which results in the change of the functional partner of TrkB.T1 from p75
NTR
 to 
adenosine receptor A2A (A2AR) in astrocytes [31]. Thereafter A2AR-mediated 
cAMP/PKA signaling dominates over ceramide-mediated CK2 and Nrf2 activities in the 
active phase. In contrast to CK2, PKA suppresses protein import into mitochondria 
leading to downregulation of oxidative phosphorylation [71] (Fig. 3 A).   
In contrast to astrocytes, neurons express both TrkB.FL and TrkB.T1 receptors, and 
BDNF-TrkB.FL-p75
NTR
 signaling does not support ceramide-CK2 dependent Nrf2 
activation. Additionally, BDNF-TrkB.FL signaling induces internalization and 
accumulation of p75
NTR
 in exosome-related multi-vesicular bodies MVBs without rapid 
degradation in neurons, and p75
NTR
-loaded exosomes can be released when neuronal 
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activity increases [74]. The expression levels of both types of TrkB.FL and TrkB.T1 
vary among neurons, and neuronal damage induces changes in the ratio of the two 
receptors [75]. Therefore, it is not clear at present whether the BDNF-TrkB.T1-p75
NTR
 
axis contributes to activation of transcription factor Nrf2 in neurons in vivo [76]. 
However, if activation of BDNF-TrkB.T1-p75
NTR
 signaling occurs locally along axons 
distal to soma, it may contribute elongation of distal dendrites [77], and 
ceramide-activated PP1 may play a role in the regulation of neurofilaments and 
transport of cargoes along axons in neurons [78,79] (Fig. 3 B). 
 
6. Neurons activate Nrf2 in astrocytes in a mixed culture  
Habas et al. [80] showed that an interaction of astrocytes and neurons is important in 
the regulation of Nrf2 activation in astrocytes. The authors cultured neurons and 
astrocytes prepared from rat embryo brain hippocampus and observed that stimulation 
of neurons with GABAA receptor antagonist gabazine and/or K
+
 channel inhibitor 
4-aminopyridine (4-AP), which induces depolarization and neurotransmitter release, 
induced Nrf2 activation in astrocytes but not in neurons. As the same treatment did not 
cause Nrf2 activation in astrocyte predominant culture, the authors suggested soluble 
factors released from stimulated neurons induced Nrf2 activation in astrocytes. It was 
also shown that release of glutamate and activation of group I metabotropic glutamate 
receptors (mGluR1 or mGluR5) during the neuronal stimulation plays a role in the 
astrocyte-specific activation of Nrf2.  
Although Habas et al. [80] did not identify the factors that cause Nrf2 activation in 
astrocytes, we propose BDNF as the major Nrf2 activation factor released during 
co-culture following depolarizing stimulation of neurons. BDNF is the main 
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neurotrophin in the brain and can be released from neurons in an activity-dependent 
manner [81]. In the BDNF-rich hippocampal circuit, BDNF is highly abundant in 
presynaptic terminals of glutamatergic neurons. Activation of presynaptic and 
postsynaptic glutamate receptors AMPAR and NMDAR is important for BDNF release 
from nerve terminals [82,83]. Notably, BDNF is synthesized as a precursor (proBDNF) 
and is secreted as either a mature furin-processed form or an unprocessed pro-form. In 
the hippocampus, secreted proBDNF is cleaved to generate mature BDNF by the 
extracellular serine protease, plasmin, which is produced from plasminogen by 
tissue-type plasminogen activator (tPA) [84,85]. Notably, activation of metabotropic 
glutamate receptor upregulates tPA protein synthesis [86]. However, cultured astrocytes 
efficiently secrete plasminogen activator inhibitor-1 (PAI-1) and suppress generation of 
plasmin [87]. Taken together, multiple glutamate receptors are involved in the control of 
proBDNF secretion from stimulated neurons and additional factors are involved in the 
generation of active mature BDNF. Additionally, astrocytes can absorb proBDNF 
released from neurons via its receptor p75
NTR
 to store proBDNF in intracellular vesicles 
and proBDNF is processed to mature BDNF before endocytic BDNF secretion [84,88]. 
However, depolarization does not secrete BDNF from astrocytes. The presence of these 
multiple steps may be the reason why it takes overnight incubation to accumulate 
mature BDNF in the medium to induce Nrf2 activation via the TrkB.T1-p75
NTR
 axis in 
astrocytes following stimulation of neurons (Fig. 4 A).  
Notably, Habas et al. [80] also showed that Nrf2 activation in astrocytes can be 
observed as early as in 2 h when the mixed culture was stimulated with 50 mmole/L K
+
.  
This effect of high K
+
 is caused by the different mechanism from the depolarization of 
neurons. We propose this effect was caused by mature BDNF released from astrocytes 
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following treatment with high K
+
. It was shown by others that stimulation with 40 
mmole/L K
+
 induces secretion of stored mature BDNF from astrocytes within 5 min 
[88]. Released mature BDNF can directly activate Nrf2 in astrocytes via 
BDNF-TRkB.T1-p75
NTR
 axis. Although, high K
+
 is an artificial condition, ATP can also 
induce rapid release of BDNF from astrocytes [88]. As astrocytes are known to secrete 
ATP through hemichannels, ATP-mediated rapid BDNF release from astrocytes seems 
to be a physiological response (Fig. 4 A). Pannexin 1 channels can be activated by 
elevations in extracellular K
+ 
[89].
 
 High K
+ 
induces a shift of activation potentials to 
more physiological range, thereby allowing channel opening at resting or slightly 
depolarized potentials [90] (Table 2). Therefore, it is plausible that high K
+
 opens 
pannexin 1 channels releasing ATP, leading to release of BDNF by the mechanism 
discussed in the next section. In conclusion, our hypothesis that BDNF synthesized in 
hippocampal neurons can activate Nrf2 in astrocytes extends the observations reported 
by Habas et al. [80].  
 
7. ATP induces release of BDNF and microparticles from astrocytes 
ATP is a widespread cell-to-cell signaling molecule in the brain and pannexin 1 
hemichannels are one of the major pathways mediating ATP release from astrocytes 
(reviewed in [91,92]. In the plasma membrane, Pannexin 1 forms a hexamer composing 
a transmembrane channel which mediates ATP release under physiological and 
pathological conditions. Each Pannexin 1 has a low affinity ATP binding site, which 
functions as a negative feedback mechanism for ATP release to prevent cell toxicity. 
Increased Ca
2+
 influx induces opening of the pannexin 1 channels leading to release of 
ATP from astrocytes (Table 2). As pannexin 1 channels have a large pore size and an 
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apparent lack of selectivity, other small molecules of the size of ATP such as glutamate 
and D-serine will pass through the channels, but we focus here on ATP.  
ATP released from astrocytes plays a key role for the release of BDNF [88] and 
microparticles [93]. Astrocytes are known to actively release divergent secretory 
organelles, including synaptic-like microvesicles and exosomes to communicate with 
other cells including neurons (reviewed in [94-96]). Exosomes are small vesicles 
generated by the trafficking of MVBs from the cytosol to the cell surface carrying 
microRNAs, mRNAs, proteins and lipids. The second type of extracellular vesicles, 
termed microvesicles or ectosomes are derived from the plasma membrane and are 
released in response to specific stimuli, such as changes in extracellular ATP levels 
[97,98].  
P2X family purinergic receptors are membrane ion channels preferably permeable to 
sodium, potassium and calcium that open within milliseconds of ATP binding. Therefore, 
over-activation of P2X channels with unphysiological, high concentrations of ATP 
induces cell death. Ectonucleotidases hydrolyze released ATP to adenosine protecting 
neuronal cells from over-activation of P2X receptors. Microglial cells and astrocytes in 
the substantia nigra in rats express P2X7 receptors. However, dopaminergic neurons in 
the substantia nigra compact in adult rat express P2X1-6R, but not P2X7R [91]. 
Activation of the P2X7R with low levels of ATP triggers a remarkably diverse array of 
membrane trafficking responses (reviewed in [99,100]). These responses can result in 
the release of bioactive proteins, including mature BDNF, lipids, and large membrane 
complexes into extracellular compartments for communication with other cells. P2X7R 
regulates shedding of plasma membrane surface proteins, exocytosis of secretory 
lysosomes and release of exosomes from multivesicular bodies. 
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8.  Transfer of membrane vesicles to neurons  
As astrocytes are known to actively release divergent secretory organelles, including 
synaptic-like microvesicles and exosomes [101,102], it is plausible that astrocytes 
systematically and time-dependently provide various molecules, including 
Nrf2-regulated gene products and/or transcripts, to neurons to protect them against 
oxidative stress. Notably, GSTM2, a key enzyme for detoxification of dopamine 
o-quinones, can be transferred from glioblastoma U373MG cells to neuronal SH-SY5Y 
cells in culture to protect the neuronal cells from reactive quinones [48]. 
Proteomics analysis has revealed that exosomes released from different types of 
cultured cells contain various proteins. Notably, among the top 50 most commonly 
identified proteins in exosome preparations [94], 5 target genes of the Nrf2-ARE axis 
actually found among upregulated genes in astrocytes stimulated with tBHQ [33]. These 
are glyceraldehyde-3-phosphate dehydrogenase, pyruvate kinase, phosphoglycerate 
kinase 1, triosephosphate isomerase and peroxiredoxin-1, with two of them highlighted 
in Table 1. Peroxiredoxins 1 and 2, and thioredoxin 1 are constantly released from 
various cultured cells under mild oxidative stress [103]. These studies suggest that 
secretion of GSTM2 from astrocytes probably depends on exosomes [48]. Ferritin is 
also secreted via the multivesicular body-exosome pathway [104]. Astrocyte-specific 
exosomes contain sortilin known as the co-receptor for p75
NTR
 in the proNGF- and 
proBDNF-induced cell death, and moreover glioblastoma cells release TrkB-containing 
exosomes [105]. Microvesicles from astrocytes also contain different types of proteins 
including Cu-Zn SOD and matrix metallopeptidases [106]. Taken together astrocytes 
can release some of the Nrf2-regulated gene products, GSTM2 and also BDNF 
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receptors p75
NTR
 and/or TrkB.T1 via exosomes and microvesicles. Further studies are 
warranted to identify the contents in these membrane particles and whether these 
modulate neuronal function. 
Neurons can physically interact with astrocytes through membrane proteins and 
mutually stimulate intracellular signaling. Thy-1 is a membrane glycoprotein expressed 
in neurons, T cells, endothelial cells and some other cell types. Thy-1 interacts with 
αvβ3 integrin and syndecan-4 expressed in astrocytes [107,108]. Thy-1 binding to αvβ3 
integrin on astrocytes triggers calcium transient and activates purinergic receptor 
P2X7R-mediated calcium entry in astrocytes [109] (Table 2). However, primary 
astrocytes express low levels of αvβ3 integrin and are unresponsive to Thy-1, 
suggesting additional factors are involved in the regulation of intercellular 
communication [110]. Notably, specific interaction of these two membrane proteins is 
used for targeted delivery of αvβ3 integrin containing extracellular vesicles to Thy-1 
expressing recipient cells [111-113]. These studies suggest that neurons may have the 
potential to efficiently receive extracellular membrane vesicles containing αvβ3 integrin 
released from nearby astrocytes using Thy-1 as the receptor.  
As neurons upregulate expression of quite different set of Nrf2 target genes compared 
to those in astrocytes (Table 1), it is a plausible scenario that astrocytes transfer to 
neurons a set of enzymes and proteins to support metabolic shifts and to protect them 
from oxidative damage during the active/dark phase. The transfer of these enzymes and 
proteins could instantly afford protection for neurons against oxidative stress. If our 
hypothesis is correct, the process is time- and energy-efficient compared to synthesis of 
proteins in the soma and transport along axons to appropriate targets. This process 
would also enable astrocytes to release unnecessary cell components via membrane 
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vesicles resulting in the shift of energy metabolism.  
 
9. Glucocorticoids regulate circadian control of ATP release from astrocytes  
Release of ATP from astrocytes under physiological conditions is regulated by 
circadian rhythm [114-116]. Primary cultures of astrocytes express circadian oscillations 
in extracellular ATP accumulation that persist for multiple cycles with periods of about 
23 h [114,115]. ATP levels in the rat SCN in vivo are also marked by rhythmic variation 
during exposure to 12 h of light and 12 h of dark, with peak accumulation occurring 
during the latter half of the dark phase or subjective night. Notably, the master clock in 
SCN is controlled by light signals and entrains subsidiary oscillators in other brain 
regions as well as many peripheral tissues. These peripheral clocks have significantly 
different time phases compared to the master clock in nocturnal animals such as rats and 
mice [117,118].  
Notably, release of ATP in the brain is controlled by plasma levels of glucocorticoids 
(GCs). The time of the day-dependent changes in the secretion of GCs from the adrenal 
glands are controlled by the SCN through the Hypothalamus-Pituitary-Adrenal 
neuroendocrine axis [119] (Fig. 5 A). GCs released from the adrenal glands play a key 
role in synchronizing subsidiary oscillators to coordinate various biological processes, 
thereby entraining daily rhythms in physiology and behavior [120,121]. The 
glucocorticoid receptor (GCR) is expressed in most cell types and GCs-GCR signaling 
induces various effects in a cell-type dependent manner [122]. Recently, Koyanagi et al. 
[123] showed GCs stimulates ATP release from spinal astrocytes in mice. Plasma levels 
of GC/corticosterone have a sharp peak before beginning of the dark/active phase and 
the extracellular ATP in the cerebrospinal fluid markedly increased in almost the same 
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time phase as corticosterone (Fig. 5 A). These authors showed that GC-GCR axis opens 
pannexin 1 channels in astrocytes, largely mediated by the activation and upregulation 
of serum- and glucocorticoid-enhanced kinase-1 (SGK-1). They further discussed that 
SGK-1 increases store-operated calcium entry via activation of Orai-1, a plasma 
membrane channel forming unit [123].  
Thus GCs-mediated sharp increases in ATP via opening of pannexin 1 channels in 
astrocytes in the brain occur just before the phase change from light/rest to dark/active 
phase in mice [123]. Increased extracellular ATP will facilitate release of BDNF and 
microparticles and exosomes from astrocytes (Fig. 4 B). As a result, BDNF stimulates 
neurons and astrocytes via autocrine/paracrine loop and microparticles and exosomes 
are transferred from astrocytes to neurons (Fig. 5 B). Thus, we speculate daily increases 
in plasma GCs stimulate astrocyte-neuron interactions in the brain to facilitate and to 
harmonize circadian phase changes, vitalizing neurons and increasing the ‘nursing 
activity’ of astrocytes through systematic material transfer from astrocytes to neurons 
(Fig. 4 B and 5). 
 
10. Summary and future perspectives 
Astrocyte-neuron interactions play a key role in iron metabolism and protection of 
neurons from ferroptosis. Astrocytes have a high capacity to store iron and prevent iron 
overload in neurons (reviewed in [4,8,9]), in part dependent on the activation of the 
Nrf2 defense pathway [29,30]. Astrocytes provide neurons with GSTM2 and other 
antioxidants to afford protection from oxidative damage. Dysregulation of 
astrocyte-neuron interactions and inadequate Nrf2 activation in astrocytes may lead to 
ferroptosis-like cell death in neurons especially dopaminergic neurons. We propose 
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BDNF plays a key role in coordinating astrocyte-neuron interactions and the circadian 
regulation of Nrf2 expression and mitochondrial activity in astrocytes. In contrast, 
BDNF may not effectively activate Nrf2 in neurons, therefore the mechanism and 
importance of Nrf2 activation in neurons in vivo remains unresolved. 
In this review, we discussed the importance of pannexin 1 hemichannels in the 
regulation of intercellular communication between astrocytes and neurons. Pannexin 1 
channels are expressed wide variety of cells and released ATP transduce signals through 
its receptors. The physical interaction of astrocytes and neurons via αvβ3 integrin and 
Thy-1 opens pannexin 1 channels [109]. In addition to direct interaction of astrocytes 
with neurons, adrenal stress hormone GCs play a key role in the circadian control of 
pannexin 1 channels and release of ATP from astrocytes in the brain [123]. Thus, GCs 
coordinate the metabolic shift from the rest into the active phase in rodents. 
Circadian regulation of p75
NTR
 must
 
play a key role in time-dependent alteration of 
BDNF-mediated signaling pathways and metabolic cooperation between astrocytes and 
neurons. Notably, over- or chronic-activation of BDNF-TrkB.T1-p75
NTR
 signaling in 
astrocytes does not favor generation of lactate to support neurons (Fig. 3 A). In contrast, 
insufficient p75
NTR
-CK2-Nrf2 signaling in astrocytes may not protect neurons from 
oxidative damage. 
Disturbances in circadian rhythms and sleep-awake cycles have been considered as 
symptoms of aging-related neurodegenerative conditions such as Alzheimer’s, 
Parkinson’s and Huntington disease (reviewed in [124-127]). Clinical studies and 
experiments in animal models of neurodegenerative disorders have revealed the 
progressive nature of circadian dysfunction throughout the course of these diseases. 
Aging has been associated with iron retention in many cell types, and in neurons, 
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promoting neurodegeneration by ferroptosis [128], which may partly be due to circadian 
dysregulation. As disruption of the circadian rhythm may be associated with inadequate 
activation of Nrf2 and dysregulation of astrocyte-neuron interactions, control of the 
circadian clock and sleep-wake cycles are particularly important for the normalization 
of brain functions and neuronal protection.  
 
Acknowledgments 
 We acknowledge support from JSPS KAKENHI Grant Number 21500386 (T.I.) and 
19790178 (E.W.) and British Heart Foundation (G.E.M., FS/15/6/31298) and Medical 
Research Council (G.E.M.). 
 
References  
[1] Y. Xie, W. Hou, X. Song, Y. Yu, J. Huang, X. Sun, R. Kang, D. Tang D, 
Ferroptosis: process and function, Cell Death Differ. 23 (2016) 369-379. 
[2] B.R. Stockwell, J.P. Friedmann Angeli, H. Bayir, A.I. Bush, M. Conrad, S.J. Dixon, 
S. Fulda, S. Gascón, S.K. Hatzios, V.E. Kagan, K. Noel, X. Jiang, A. Linkermann, 
M.E. Murphy, M. Overholtzer, A. Oyagi, G.C. Pagnussat, J. Park, Q. Ran, C.S. 
Rosenfeld, K. Salnikow, D. Tang, F.M. Torti, S.V. Torti, S. Toyokuni, K.A. 
Woerpel, D.D. Zhang, Ferroptosis: A regulated cell death nexus linking metabolism, 
Redox Biology, and Disease, Cell. 171 (2017) 273-285. doi: 
10.1016/j.cell.2017.09.021.  
[3] D.J.R. Lane, S. Ayton, A.I. Bush, Iron and Alzheimer’s disease: an update on 
emerging mechanisms, J. Alzheimers Dis. (in press) (2018). doi: 
25 
 
10.3233/JAD-179944. 
[4] F. Codazzi, I. Pelizzoni, D. Zacchetti, F. Grohovaz, Iron entry in neurons and 
astrocytes: a link with synaptic activity, Front. Mol. Neurosci. 8 (2015)18. doi: 
10.3389/fnmol.2015.00018. 
[5] D.J. Lane, S.R. Robinson, H. Czerwinska, G.M. Bishop, A. Lawen, Two routes of 
iron accumulation in astrocytes: ascorbate-dependent ferrous iron uptake via the 
divalent metal transporter (DMT1) plus an independent rout for ferric iron, 
Biochem. J. 432 (2010) 123-132. 
[6] G.M. Bishop, I.F. Scheiber, R. Dringen, S.R. Robinson, Synergistic accumulation of 
iron and zinc by cultured astrocytes. J Neural accumulation of iron and zinc by 
cultured astrocytes, J. Neural. Transm. 117 (2010) 809-817. 
[7] I. Pelizzoni, D. Zacchetti, A. Campanella, F. Grohovaz, F. Codazzi, Iron uptake in 
quiescent and inflammation-activated astrocytes: a potentially neuroprotective 
control of iron burden, Biochem. Biophys. Acta. 1832 (2013) 1326-1333. 
[8] M.C. Hohnholt, R. Dringen, Uptake and metabolism of iron and iron oxide 
nanoparticles in brain astrocytes, Biochem. Soc. Trans. 41 (2013) 1588-1592. 
[9] G. Morris, M. Berk, A.F. Carvalho, M. Maes, A.J. Walker, B.K. Puri, Why should 
neuroscientists worry about iron? The emrging role of ferroptosis in the 
pathophysiology of neuroprogressive diseases, Behav. Brain Res. 341 (2018) 
154-175. 
[10] Y. Zhang, D. Wan, X. Zhou, C. Long, X. Wu, L. Li, L. He, P. Huang, S. Chen, B. 
Tan, Y. Yin, Diurnal variations in iron concentrations and expression of genes 
involved in iron absorption and metabolism in pigs, Biochem. Biophys. Res. 
Commun. 490 (2017) 1210-1214.  
26 
 
[11] M. Fricker, A.M. Tolkovsky, V. Borutaite, M. Coleman, G.C. Brown, Neuronal cell 
death, Physiol. Rev. 98 (2018) 813-880. doi: 10.1152/physrev.00011.2017. 
[12] S. Genoud , B.R. Roberts, A.P. Gunn, G.M. Halliday, S.J.G. Lewis, H.J. Ball, D.J. 
Hare, K.L. Double, Subcellular compartmentalization of copper, iron, manganese, 
and zinc in the Parkinson’s disease brain, Metallomics. 9 (2017)1447-1455. 
[13] J.R. Liddell, A.R. White, Nexus between mitochondrial function, iron, copper and 
glutathione in Parkinson’s disease, Neurochem. Int. (2017) S0197-0186(17)30250-4. 
Doi: 10.1016/j.neuint.2017.05.016. 
[14] B. Do Van, F. Gouel, A. Jonneaux, K. Timmerman, P. Gelé, M. Pétrault, M. Bastide, 
C. Laloux, C. Moreau, R. Bordet, D. Devos, J.C. Devedjian, Ferroptosis, a newly 
characterized form of cell death in Parkinson’s disease that is regulated by PKC, 
Neurobiol. Dis. 94 (2016) 169-178. 
[15] S.J. Guiney, P.A. Adlard, A.I. Bush, D.I. Finkelstein, S. Ayton, Ferroptosis and cell 
death mechanisms in Parkinson’s disease, Neurochem. Int. 104 (2017) 34-48. 
[16] P. Muñoz, I. Paris, J. Segura-Aguilar, Commentary: Evaluation of models of 
Parkinson’s disease, Front. Neurosci. 10 (2016) 161. Doi: 
10.3389/fnins.2016.00161. 
[17] R. Sugimoto, Y. Kumagai, Y. Nakai, T. Ishii T, 9,10-Phenanthraquinone in diesel 
exhaust particles downregulates Cu,Zn-SOD and HO-1 in human pulmonary 
epithelial cells: Intracellular iron scavenger 1,10-phenanthroline affords protection 
against apoptosis, Free Radic. Biol. Med. 38 (2005) 388-395. 
[18] L. Zecca, R. Pietra, C. Goj, C. Mecacci, D. Radice, E. Sabbioni, Iron and other 
metals in neuromelanin, susbtantia nigra, and putamen of human brain, J. 
Neurochem. 62 (1994) 1097-1101. 
27 
 
[19] L. Zecca, M. Gallorini, V. Schünemann, A.X. Trautwein, M. Gerlach, P. Riederer, P. 
Vezzoni, D. Tampellini, Iron, neuromelanin and ferritin content in the substantia 
nigra of normal subjects at different ages: consequences for iron storage and 
neurodegenerative processes, J. Neurochem. 76 (2001) 1766-1773.  
[20] E.L. Unger, L.E. Bianco, B.C. Jones, R.P. Allen, C.J. Earley, Low brain iron effects 
and revesrsibility on striatal dopamine dynamics, Exp. Neurol. 261 (2014) 462-468.  
[21] A. Bindoli, Lipid peroxidation in mitochondria, Free Radic. Biol. Med. 5 (1988) 
247-261. 
[22] P. Jenner, Oxidative stress as a cause of Parkinson’s disease, Acta Neurol. Scand. 
Suppl. 136 (1991) 6-15. 
[23] J.C. Fernández-Checa, N. Kaplowitz, C. García-Ruiz, A. Colell, M. Miranda, M. 
Marí, E. Ardite, A. Morales, GSH transport in mitochondria: defense against 
TNF-induced oxidative stress and alcohol-induced defect, Am. J. Physiol. 273 
(1997) 273:G7-17. 
[24] J.I. Sagara, K. Miura, S. Bannai, Maintenance of neuronal glutathione by glial cells, 
J. Neurochem. 61 (1993) 1672-1676. 
[25] T. Ishii, G.E. Mann, Redox status in mammalian cells and stem cells during culture 
in vitro: critical roles of Nrf2 and cystine transporter activity in the maintenance of 
redox balance, Redox Biol. 2 (2014) 786-794. Doi: 10.1016/j.rodox.2014.04.008. 
[26] K. Itoh, T. Chiba, S. Takahashi, T. Ishii, K. Igarashi, Y. Katoh, T. Oyake, N. 
Hayashi, K. Satoh, I. Hatayam, M. Yamamoto, Y. Nabeshima, An Nrf2/small Maf 
heterodimer mediates the induction of phase II detoxifying enzyme genes through 
antioxidant response elements, Biochem. Biophys. Res. Commun. 236 (1997) 
313-322. 
28 
 
[27] T. Ishii, K. Itoh, S. Takahashi, H. Sato, T. Yanagawa, Y. Katoh, S. Bannai, M. 
Yamamoto, Transcription factor Nrf2 coordinately regulates a group of oxidative 
stress-inducible genes in macrophages, J. Biol. Chem. 275 (2000) 16023-16029. 
[28] G.E. Mann, H.J. Forman, Introduction to Special Issue on ‘Nerf2 regulated redox 
signaling and metabolism in physiology and medicine’, Free Radic. Biol. Med. 88 
(2015) 91-92. 
[29] Z. Cui, Z. Zhong, Y. Yang, B. Wang, Y. Sun, Q. Sun, G.Y. Yang, L. Bian, Ferrous 
iron induces Nrf2 expression in mouse brain astrocytes to prevent neurotoxicity, J. 
Biochem. Mol. Toxicol. 30 (2016) 396-403.  
[30] M.J. Kerins, A. Ooi, The role of NRF2 in modulating cellular iron homeostasis, 
Antioxid. Redox Signal. (2017) [Epub ahead of print] doi: 10.1089/ars.2017.7176. 
[31] T. Ishii T, E. Warabi, G.E. Mann, Circadian control of p75 neurotrophin receptor 
leads to alternate activation of Nrf2 and c-Rel to reset energy metabolism in 
astrocytes via brain-derived neurotrophic factor, Free Radic. Biol Med. 119 (2018) 
34-44. doi: 10.1016/j.freeradbiomed.2018.01.026.  
[32] Z.C. Baquet, P.C. Bickford, K.R. Jones, Brain-derived neurotrophic factor is 
required for the establishment of the proper number of dopaminergic neurons in the 
substantia nigra pars compacta, J. Neurosci. 25 (2005) 6251-6259. 
[33] A.D. Kraft, D.A. Johnson, J.A. Johnson, Nuclear factor E2-related factor 
2-dependent antioxidant response element activation by tert-butylhydroquinone and 
sulforaphane occurring preferentially in astrocytes conditions neurons against 
oxidative insult, J. Neurosci. 24 (2004) 1101-1112. 
[34] S. Bannai, H. Tsukeda, H. Okumura, Effect of antioxidants on cultured human 
diploid fibroblasts exposed to cystine-free medium, Biochem. Biophys. Res. 
29 
 
Commun. 74 (1977) 1582-1588. 
[35] S. Bannai, Exchange of cystine and glutamate across plasma membrane of human 
fibroblasts, J. Biol. Chem. 261 (1986) 2256-2263. 
[36] S. Bannai, Transport of cystine and cysteine in mammalian cells, Biochim. Biophys. 
Acta. 779 (1984) 289-306. 
[37] H. Sato, M. Tamba, S. Okuno, K. Sato, K. Keino-Masu, M. Masu, S. Bannai, 
Distribution of cystine/glutamate exchange transporter, system xc-, in the mouse 
brain, J. Neurosci. 22 (2002) 8028-8033. 
[38] H. Sato, A. Shiiya, M. Kimata, K. Maebara, M. Tamba, Y. Sakakura, N. Makino, F. 
Sugiyama, K. Yagami, T. Moriguchi, S. Takahashi, S. Bannai, Redox imbalance in 
cystine/glutamate transporter-deficient mice, J. Biol. Chem. 280 (2005) 
37423-37429. 
[39] S. Ottestad-Hansen, Q.X. Hu, V.V. Follin-Arbelet, E. Bentea, H. Sato, A. Massie, Y. 
Zhou, N.C. Danbolt, The cystine-glutamate exchanger (xCT, Slc7a11) is expressed 
in significant concentrations in a subpopulation of astrocytes in the mouse brain, 
Glia 66 (2018) 951-970. 
[40] H. Sasaki, H. Sato, K. Kuriyama-Matsumura, K. Sato, K. Maebara, H. Wang, M. 
Tamba, K. Itoh, M. Yamamoto, S. Bannai, Electrophile response element-mediated 
induction of the cystine/glutamate exchange transporter gene expression, J. Biol. 
Chem. 277 (2002) 44765-44771. 
[41] P. Ye, J. Mimura, T. Okada, H. Sato, T. Liu, A. Maruyama, C. Ohyama, K. Itoh, 
Nrf2- and ATF4-dependent upregulation of xCT modulates the sensitivity of T24 
bladder caricinoma cells to proteasome inhibition, Mol. Cell. Biol. 34 (2014) 
3421-3434. 
30 
 
[42] X. Liu, R. Albano, D. Lobner, FGF-2 induces neuronal death through upregulation 
of system xc-, Brain Res. 1547 (2014) 25-33. 
[43] Y. Fei, L. Xiao, M.M. Hurley, Fibroblast growth factor 2 positively regulates 
expression of activating transcription factor 4 in osteoblasts, Biochem. Biophys. 
Res. Commun. 391 (2010) 335-339. 
[44] K.P. Malabanan, P. Kanellakis, A. Bobik, L.M. Khachigian, Activation 
transcription factor-4 induced by fibroblast growth factor-2 regulates vascular 
endothelial growth factor-A transcription in vascular smooth muscle cells and 
mediates intimal thickening in rat arteries following balloon injury, Circ. Res. 103 
(2008) 378-387.  
[45] N. Wei, L.Q. Zhu, D. Liu, ATF4: a novel potential therapeutic target for 
Alzheimer’s disease, Mol. Neurobiol. 52 (2015) 1765-1770. 
[46] A.D. Kraft, J.M. Lee, D.A. Johnson, Y.W. Kan, J.A. Johnson, Neuronal sensitivity 
to kainic acid is dependent on the Nrf2-mediated actions of the antioxidant response, 
J. Neurochem. 98 (2006) 1852-1865. 
[47] L.O. Hansson, R. Bolton-Grob, M. Widersten, B. Mannervik, Structural 
determinants in domain II of human glutathione transferase M2-2 govern the 
characteristic activities with aminochrome, 
2-cyano-1,3-dimethyl-1-nitrosoguanidine, and 1,2-dichloro-4-nitrobenzene, Protein 
Sci. 8 (1999) 2742-2750. 
[48] C. Cuevas, S. Huenchuguala, P. Muñoz, M. Villa, I. Paris, B. Mannervik, J. 
Segura-Aguilar, Glutathione transferase-M2-2 secreted from glioblastoma cell 
protects SH-SY5Y cells from aminochrome neurotoxicity, Neurotox. Res. 27 
(2015) 217-228. 
31 
 
[49] W.S. Hambright, R.S. Fonseca, L. Chen, R. Na, Q. Ran, Ablation of ferroptosis 
regulator glutathione peroxidase 4 in forebrain neurons promotes cognitive 
impairment and neurodegeneration, Redox Biol. 12 (2017) 8-17.  
[50] A.B. Fisher, Peroxiredoxin 6: a bifunctional enzyme with glutathione peroxidase 
and phospholipase A2 activities, Antioxid. Redox Signal. 15 (2011) 831-844. 
[51] T. Eismann, N. Huber, T. Shin, S. Kuboki, E. Galloway, M. Wyder, M.J. Edwards, 
K.D. Greis, H.G. Shertzer, A.B. Fisher, A.B. Lentsch, Peroxiredoxin-6 protects 
against mitochondrial dysfunction and liver injury during ischemia-reperfusion in 
mice, Am. J. Physiol. Gastrointest. Liver Physiol. 296 (2009) G266-274. 
[52] S. Ma, X. Zhang, L. Zhang, Z. Li, X. Zhao, W. Lai, H. Shen, J. Lv, G. Yang, Q. 
Wang, J. Ji, Peroxiredoxin 6 is a crucial factor in the initial step of mitochondrial 
clearance and is upstream of the PINK1-Parkin pathway, Antioxid. Redox Signal. 
24 (2016) 486-501. 
[53] E.C. Pietsch, J.Y. Chan, F.M. Torti, S.V. Torti, Nrf2 mediates the induction of 
ferritin H in response to xenobiotics and cancer chemopreventive dithiolethiones, J. 
Biol. Chem. 278 (2003) 2361-2369. 
[54] I. Lastres-Becker, A.J. Garcia-Yagüe, R.H. Scannevin, M.J. Casarejos, S. Kügler, 
A. Rábano, A. Cuadrado, Repurposing the NRF2 activator dimethyl fumarate as 
therapy against synucleinopathy in Parkinson’s disease, Antioxid. Redox Signal. 25 
(2016) 61-77.  
[55] M. Ahuja, N. Ammal Kaidery, L. Yang, N. Calingasan, N. Smirnova, A. Gaisin, 
I.N. Gaisina, I. Gazaryan, D.M. Hushpulian, I. Kaddour-Djebbar, W.B. Bollag, J.C. 
Morgan, R.R. Ratan, A.A. Starkov, M.F. Beal, B. Thomas, Distinct Nrf2 signaling 
mechanisms of fumaric acid esters and their role in neuroprotection against 
32 
 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced experimental 
Parkinson’s-like disease, J. Neurosci. 36 (2016) 6332-6351.  
[56] H.C. Au, B.B. Seo, A. Matsuno-Yagi, T. Yagi, I.E. Scheffler, The NDUFA1 gene 
product (MWFE protein) is essential for activity of complex I in mammalian 
mitochondria, Proc. Natl. Acad. Sci. USA. 96 (1999) 4354-4359. 
[57] M. Boerries, P. Most, J.R. Gledhill, J.E. Walker, H.A. Katus, W.J. Koch, U. Aebi, 
C.A. Schenenberger, Ca
2+
-dependent interaction of S100A1 with F1-ATPase leads 
to an increased ATP content in cardiomyocytes, Mol. Cell Biol. 27 (2007) 
4365-4373. 
[58] K. Kosaka, J. Miura, K. Itoh, T. Satoh, Y. Shimojo, C. Kitajima, A. Maruyama, M. 
Yamamoto, T. Shirasawa, Role of Nrf2 and p62/ZIP in the neurite outgrowth by 
carnosic acid in PC12h cells, J. Biochem. 147 (2010) 73-81. 
[59] R.T. Dobrowsky, M.H.Werner, A.M. Castellino, M.V. Chao, Y.A. Hannun, 
Activation of the sphinogomyelin cycle through the low-affinity neurotrophin 
receptor, Science 265 (1994) 1596-1599.  
[60] A. Blöchl, C. Sirrenberg, Neurotrophins stimulate the release of dopamine from rat 
mesencephalic neurons via Trk and p75Lntr receptors, J. Biol. Chem. 271 (1996) 
21100-21107. 
[61] G. Müller, M. Ayoub, P. Storz, J. Rennecke, D. Fabbro, K. Pfizenmaier, PKCζ is a 
molecular switch in signal transduction of TNF-α, bifunctionally regulated by 
ceramide and arachidonic acid, EMBO J. 14 (1995) 1961-1969. 
[62] P.L. Apopa, X. He, Q. Ma, Phosphorylation of Nrf2 in the transcription activation 
domain by casein kinase 2 (CK2) is critical for the nuclear translocation and 
transcription activation function of Nrf2 in IMR-32 neuroblastoma cells, J. 
33 
 
Biochem. Mol. Toxicol. 22 (2008) 63-76. 
[63] T. Afonyuskin, O.V. Oskolkova, B.R. Binder, V.N. Bochkov, Involvement of CK2 
in activation of electrophilic genes in endothelial cells by oxidized phospholipids, J. 
Lipid Res. 52 (2011) 98-103.  
[64] B. Baeza-Raja, K. Eckel-Mahan, L. Zhang, E. Vagena, I.F. Tsigelny, P. 
Sassone-Corsi, L.J. Ptácek, K. Akassoglou, p75 neurotrophin receptor is a clock 
gene that regulates oscillatory components of circadian and metabolic networks, J. 
Neurosci. 33 (2013) 10221-10234. 
[65] I. Schmutz , J.A. Ripperger, S. Baeriswyl-Aebischer, U. Albrecht, The mammalian 
clock component PERIOD2 coordinates circadian output by interaction with 
nuclear receptors, Genes Dev. 24 (2010) 345-357. 
[66] X. Zhao, H. Cho, R. Yu, A.R. Atkins, M. Downes, R.M. Evans, Nuclear receptor 
rock around the clock, EMBO Rep. 15 (2014) 518-528. 
[67] S. Hood, P. Cassidy, M.-P. Cossette, Y. Weigl, M. Verwey, B. Robinson, J. Stewart, 
S. Amir, Endogenous dopamine regulates the rhythm of expression of the clock 
protein PER2 in the rat dorsal striatum via daily activation of D2 dopamine 
receptors, J. Neurosci. 30 (2010) 14046-14058. 
[68] E.W. Lamont, B. Robinson, J. Stewart, S. Amir, The central and basolateral nuclei 
of the amygdala exhibit opposite diurnal rhythms of expression of the clock protein 
Period2, Pros Natl Acad USA. 102 (2005) 4180-4184. 
[69] S. Chung, E.J. Lee, S. Yun, H.K. Choe, S.B. Park, H.J. Son, K.S. Kim, D.E. Dluzen, 
I. Lee, O. Hwang, G.H. Son, K. Kim. Impact of circadian nuclear receptor 
REV-ERBα on midbrain dopamine production and mood regulation, Cell 157 
34 
 
(2014) 858-868. 
[70] J. Jager, W.T. O’Brien, J. Manlove, E.N. Krizman, B. Fang, Z. Gerhart-Hines, M.B. 
Robinson, P.S. Klein, M.A. Lazar, Benhavioral changes and dopaminergic 
dysregulation in mice lacking the nuclear receptor Rev-erbα, Mol. Endocrinol. 28 
(2014) 490-498. 
[71] C. Gerbeth, O. Schmidt, S. Rao, A.B. Harbauer, D. Mikropoulou, M. Opalińska, B. 
Guiard, N. Pfanner, C. Meisinger, Glucose-induced regulation of protein import 
receptor Tom22 by cytosolic and mitochondria-bound kinases, Cell Metab. 18 
(2013) 578-587. 
[72] C.E. Chalfant, K. Kishikawa, M.C. Mumby, C. Kamibayashi, A. Bielawska, Y.A. 
Hannun, Long chain ceramide activate protein phosphatase-1 and protein 
phosphatase-2A. Activation is stereospecific and regulated by phosphatidic acid, J. 
Biol. Chem. 274 (1999) 20313-20317. 
[73] P.J. Roach, A.A. Depaoli-Roach, T.D. Hurley, V.S. Tagliabracci, Glycogen and its 
metabolism: some new developments and old themes, Biochem. J. 441 (2012) 
763-787. 
[74] C.A. Escudero, O.M. Lazo, C. Galleguillos, J.I. Parraguez, M.A. Lopez-Verrilli, 
M.P. Marzolo, B.D. Carter, F.A. Court, F.C. Bronfman, The p75 neurotrophin 
receptor evades the endolysosomal route in neuronal cells, favouring multivesicular 
bodies specialized for exsosomal release, J. Cell Sci. 127 (2014) 1966-1979. 
[75] J.R. Gomes, J.T. Costa, C.V. Melo, F. Felizzi, P. Monteiro, M.J. Pinto, A.R. Inácio, 
T. Wieloch, R.D. Almeida, M. Grãos, C.B. Duarte, Excitotoxicity downregulates 
TrkB.FL signaling and upregulates the neuroprotective truncated TrkB receptors in 
cultured hippocampal and striatal neurons, J. Neurosci. 32 (2012) 4610-4622. 
35 
 
[76] T. Ishii, G.E. Mann, When and how does BDNF activate Nrf2 in astrocytes and 
neurons? Neural Regen. Res. 13 (2018) 803-804. doi: 10.4103/1673-5374.232468  
[77] T.A. Yacoubian, D.C. Lo, Truncated and full-length TrkB receptors regulate distinct 
modes of dendritic growth. Nat. Neurosci. 3 (2000) 342-349. 
[78] S. Strack, R.S. Weatphal, R.J. Colbran, F.F. Ebner, B.E. Wadzinski, Protein 
serine/threonine phosphatase 1 and 2A associate with and dephosphorylate 
neurofilaments, Brain Res. Mol. Brain Res. 49 (1997) 15-28. 
[79] G. Morfini, G. Szebenyi, H. Brown, H.C. Pant, G. Pigino, S. DeBoer, U. Beffert, 
S.T. Brady, A novel CDK5-dependent pathway for regulating GSK3 activity and 
kinesin-deriven motility in neurons, EMBO J. 23 (2004) 2235-2245. 
[80] A. Habas, J. Hahn, X. Wang, M. Margeta, Neuronal activity regulates astrocytic 
Nrf2 signaling, Proc. Natl. Acad. Sci. USA. 110 (2013)18291-18296. 
[81] N. Kuczewski, C. Porcher, V. Lessmann, I. Medina, J.L. Gaiarsa, Back-propagating 
action potential: A key contributor in activity-dependent dendritic release of 
BDNF, Commun. Integr. Biol. 1 (2008)153-155.  
[82] H. Park, A. Popescu, M.M. Poo, Essential role of presynaptic NMDA receptors in 
activity-dependent BDNF secretion and corticostriatal LTP, Neuron 84 (2014) 
1009-1022. 
[83] Y.H. Wong, C.M. Lee, W. Xie, B. Cui, M.M. Poo, Activity-dependent BDNF 
release via endocytic pathways is regulated by synaptotagmin-6 and complexin, 
Proc. Natl. Acad. Sci. USA. 112 (2015) E4475-4484. 
[84] M. Sasi, B. Vignoli, M. Canossa, R. Blum, Neurobiology of local and intercellular 
BDNF signaling, Eur. J. Physiol. 469 (2017) 593-610. 
[85] K. Gray, V. Ellis, Activation of pro-BDNF by the pericellular serine protease 
36 
 
plasmin, FEBS Lett. 582 (2008) 907-910. 
[86] C.Y. Shin, M. Kundel, D.G. Wells, Rapid, activity-induced increase in tissue 
plasminogen activator is mediated by metabotropic glutamate 
receptor-dependent mRNA translation, J. Neurosci. 24 (2004) 9425-9433. 
[87] Y. Liu, S. Honda, S. Kohsaka, K. Nakajima, Plasminogen enhances the secretion of 
plasminogen activator inhibitor-1 from cultured rat astrocytes, Neurosci. Lett. 
282 (2000) 137-140. 
[88] B. Vignoli, M. Canossa, Glioactive ATP controls BDNF recycling in cortical 
astrocytes, Commun. Integr. Biol. 10 (2017) e1277296. doi: 
10.1080/19420889.2016.1277296. 
[89] J. Wang, C. Ambrosi, F. Qiu, D.G. Jackson, G. Sosinsky, G. Dahl, The membrane 
protein Pannexin1 forms two open-channel conformations depending on the 
mode of activation, Sci. Signal. 7 (2014) ra69. doi: 10.1126/scisignal.2005431. 
[90] E. Scemes, D.C. Spray, Extracellular K
+
 and astrocyte signaling via connexin and 
pannexin channels, Neurochem. Res. 37 (2012) 2310-2316. 
[91] K. Puchałowicz, M. Tarnowski, I. Baranowska-Bosiacka, D. Chlubek, V. 
Dziedziejko, P2X and P2Y receptors-role in the pathophysiology of the nervous 
system, Int. J. Mol. Sci. 15 (2014) 23672-23704. doi: 10.3390/ijms151223672. 
[92] B.S. Khakh, R.A. North, Neuromodulation by extracellular ATP and P2X receptors 
in the CNS, Neuron. 76 (2012) 51-69. doi: 10.1016/j.neuron.2012.09.024. 
[93] F. Bianco, C. Perrotta, L. Novellino, M. Francolini, L. Riganti, E. Menna, L. 
Saglietti, E.H. Schuchman, R. Furlan, E. Clementi, M. Matteoli, C. Verderio, Acid 
sphingomyelinase activity triggers microparticle release from glial cells, EMBO J. 
28 (2009) 1043-1054. 
37 
 
[94] M. Basso, V. Bonetto, Extracellular vesicles and a novel form of communication in 
the brain, Front. Neurosci. 10 (2016)127. doi: 10.3389/fnins.2016.00127. 
[95] A. Verkhratsky, M. Matteoli, V. Parpura, J.P. Mothet, R. Zorec, Astrocytes as 
secretory cells of the central nervous system: idiosyncrasies of vesicular secretion, 
EMBO J. 35 (2016) 239-57. doi: 10.15252/embj.201592705. 
[96] N. Vardjan, V. Parpura, R. Zorec, Loos excitation-secretion coupling in astrocytes, 
Glia.64 (2016) 655-667. doi: 10.1002/glia.22920.  
[97] M. Colombo, G. Raposo, C. Théry, Biogenesis, secretion, and intercellular 
interactions of exosomes and other extracellular vesicles, Annu. Rev. Cell Dev. Biol. 
30 (2014) 255-289.  
[98] E. Cocucci, J. Meldolesi, Ectosomes and exosomes: shedding the confusion 
between extracellular vesicles, Trends. Cell Biol. 25 (2015) 364-372. 
[99] Y. Qu, G.R. Dubyak, P2X7 receptors regulate multiple types of membrane 
trafficking responses and non-classical secretion pathways, Purinergic Signal. 5 
(2009) 163-173.  
[100] R.A. North, P2X receptors, Philos Trans R Soc Lond B Biol Sci. (2016) 371. doi: 
10.1098/rstb.2015.0427. 
[101] A. Verkhratsky, M. Matteoli, V. Parpura, J.P. Mothet, R. Zorec. Astrocytes as 
secretory cells of the central nervous system: idiosyncrasies of vesicular secretion, 
EMBO J. 35 (2016) 239-257. 
[102] N. Vardjan, V. Parpura, R. Zorec, Loose excitation-secretion coupling in 
astrocytes, Glia 64 (2016) 655-667. 
[103] P. Checconi, S. Salzano, L. Bowler, L. Mullen, M. Mengozzi, E.M. 
38 
 
Hanschmann,C.H.  Lillig, R. Sgarbanti, S. Panella, L. Nencioni, A.T. Palamara, P. 
Ghezzi, Redox proteomics of the inflammatory secretome identifies a common set 
of redoxins and other glutathionylated proteins released in inflammation, influenza 
virus infection and oxidative stress, PLoS One. 10 (2015) e0127086. doi: 
10.1371/journal.pone.0127086. 
[104] M. Truman-Rosentsvit, D. Berebaum, L. Spektor, L.A. Cohen, S. 
Belizowsky-Moshe, L. Lifshitz, J. Ma, W. Li, E. Kesselman, I. Abutbul-lonita, D. 
Danino, L. Gutierrez, H. Li, K. Li, H. Lou, M. Regoni, M. Poli, F. Glaser, T.A. 
Rouault, E.G. Meyron-Holtz, Ferritin is secreted via 2 distinct nonclassical 
vesicular pathways. Blood 131 (2018) 342-352.  
[105] S. Pinet, B. Bessette, N. Vedrenne, A. Lacroix, L. Richard, M.O. Jauberteau, S. 
Battu, F. Lalloué, TrkB-containing exosomes promote the transfer of glioblastoma 
aggressiveness to YKL-40-inactivated glioblastoma cells, Oncotarget. 7 (2016) 
50349-50364. doi: 10.18632/oncotarget.10387. 
[106] M. Basso, V. Bonetto, Extracellular Vesicles and a Novel Form of Communication 
in the Brain, Front. Neurosci.10 ( 2016) 127. doi: 10.3389/fnins.2016.00127.  
[107] T. Hermosilla, D. Muñoz, R. Herrera-Molina, A. Valdivia, N. Muños, S.U. Nham, 
P. Schneider, K. Burridge, A.F. Quest, L. Leyton, Direct Thy-1/αvβ3 integrin 
interaction mediates neuron to astrocyte communication, Biochim. Biophys. Acta. 
1783 (2008) 1111-1120. 
[108] A.M. Avalos, A.D. Valdivia, N. Muñoz, R. Herrera-Molina, J.C. Tapia, S. 
Lavandero, M. Chiong, K. Burridge, P. Scheider, A.F. Quest, L. Leyton, Neuronal 
Thy-1 induces astrocyte adhesion by engaging syndecan-4 in a cooperative 
interaction with αvβ3 integrin that activates PKCα and RhoA, J. Cell Sci. 122 
39 
 
(2009) 3462-3471. 
[109] M. Henríquez, R. Herrera-Molina, A. Valdivia, A. Alvarez, M. Kong, N. Muñoz, V. 
Eisner, E. Jaimovich, P. Schneider, A.F. Quest, L. Leyton, ATP release due to 
Thy-a-integrin binding induces P2X7-mediated calcium entry required for focal 
adhesion formation, J. Cell Sci. 124 (2011) 1581-1588. 
[110] R. Lagos-Cabré, A. Alvarez, M. Kong, F. Burgos-Bravo, A. Cárdenas, E. 
Rojas-Mancilla, R. Pérez-Nuñez, R. Herrera-Molina, F. Rojas, P. Schneider, M. 
Herrera-Marschitz, A.F.G. Quest, B. van Zundert, L. Leyton, αvβ3 Integrin 
regulates astrocyte reactivity, J. Neuroinflammation. 14 (2017) 194. doi: 
10.1186/s12974-017-0968-5. 
[111] T.P. Shentu, T.S. Huang, M. Cernelc-Kohan, J. Chan, S.S. Wong, C.R. Espinoza, 
Tan C, I. Gramaglia, H. van der Heyde, S. Chien, J.S. Hagood, Thy-1 dependent 
uptake of mesenchymal stem cee-derived extracellular vesicles blocks 
myofibroblastic differentiation, Sci. Rep. 7 (2017) 18052. Doi: 
10.1038/s41598-017-18288-9. 
[112] A. Hoshino, B. Costa-Silva, T.L. Shen, G. Rodrigues, A. Hashimoto, M. Tesic 
Mark, H. Molina, S. Kohsaka, A. Di Giannatale, S. Ceder, S. Singh, C. Williams, N. 
Soplop, K. Uryu, L. Pharmer, T. King, L. Bojmar, A.E. Davies, Y. Ararso, T. Zhang, 
H. Zhang, J. Hernandez, J.M. Weiss, V.D. Dumont-Cole, K. Kramer, L.H. Wexler, 
A. Narendran, G.K. Schwartz, J.H. Healey, P. Sandstrom, K.J. Labori, E.H. Kure, 
P.M. Grandgenett, M.A. Hollingsworth, M. de Sousa, S. Kaur, M. Jain, K. Mallya, 
S.K. Batra, W.R. Jarnagin, M.S. Brady, O. Fodstad, V. Muller, K. Pantel, A.J. Minn, 
M.J. Bissell, B.A. Garcia, Y. Kang, V.K. Rajasekhar, C.M. Ghajar, I. Matei, H. 
Peinado, J. Bromberg, D, Tumour exosome integrins determine organotropic 
40 
 
metastasis, Nature. 527 (2015) 329-35. doi: 10.1038/nature15756.  
[113] A. Singh, C. Fedele, H. Lu, M.T. Nevalainen, J.H. Keen, L.R. Languino, 
Exosome-mediated transfer of αvβ3 integrin from tumorigenic to nontumorigenic 
cells promotes a migratory phenotype, Mol. Cancer Res. 14 (2016) 1136-1146. 
[114] A.D. Womac, J.F. Burkeen, N. Neuendorgg, D.J. Earnest, M.J. Zoran. Circadian 
rhythms of extracellular ATP accumulation in suprachiasmatic nucleus cells and 
cultured astrocytes, Eur. J. Neurosci. 30 (2009) 869-876. 
[115] L. Marpegan, A.E. Swanstrom, K. Chung, T. Simon, P.G. Haydon, S.K. Khan, 
A.C. Liu, E.D. Herzog, C. Beaulé, Circadian regulation of ATP release in astrocytes, 
J. Neurosci. 31 (2011) 8342-8350. 
[116] J.F. Burkeen, A.D. Womac, D.J. Earnest, M.J. Zoran, Mitochondrial calcium 
signaling mediates rhythmic extracellular ATP accumulation in suprachiasmatic 
nucleus astrocytes, J. Neurosci. 31 (2011) 8432-8440.  
[117] M.H. Hastings, A.B. Reddy, E.S. Maywood, A clockwork web: circadian timing in 
brain and periphery, in health and disease, Nat. Rev. Neurosci. 4 (2003) 649-661.  
[118] V.L. Harbour, Y. Weigl, B. Robinson, S. Amir, Phase differences in expression of 
circadian clock genes in the central nucleus of the amygdala, dentate gyrus, and 
suprachiasmatic nucleus in the rat, PLos One. 9 (2014) e103309. doi: 
10.1371/journal.pone.0103309.  
[119] R.Y. Moore, V.B. Eichler, Loss of a circadian adrenal corticosterone rhythm 
following suprachiasmatic lesions in the rat, Brain Res. 42 (1972) 201-206. 
[120] E.L. Meyer-Bernstein, A.E. Jetton, S.I. Matsumoto, J.F. Markuns, M.N. Lehman, 
E.L. Bittman, Effects of suprachiasmatic trnasplants on circadian rhythms of 
neuroendocrine function in golden hamsters, Endocrinol. 140 (1999) 207-218. 
41 
 
[121] M. Cuesta, N. Cermakian, D.B. Boivin, Glucocorticoids entrain molecular clock 
components in human peripheral cells, FASEB J. 29 (2015) 1360-1370. 
[122] G.H. Son, S. Chung, K. Kim, The adrenal peripheral clock: glucocorticoid and the 
circadian timing system, Front. Neuroendocrinol. 32 (2011) 451-465. 
[123] S. Koyanagi, N. Kusunose, M. Taniguchi, T. Akamine, Y. Kanado, Y. Ozono, T. 
Masuda, Y. Kohro, N. Matsunaga, M. Tsuda, M.W. Salter, K. Inoue, S. Ohdo, 
Glucocorticoid regulation of ATP release from spinal astrocytes underlies diurnal 
exacerbation of neuropathic mechanical allodynia, Nat. Commun. 7 (2016) 13102. 
doi: 10.1038/ncomms13102. 
[124] A.B. Reddy, J.S. O’Neill, Healthy clocks, healthy body, healthy mind, Trends. 
Cell. Biol. 20 (2010) 36-44. 
[125] A. Videnovic, A.S. Lazar, R.A. Barker, S. Overeem, ‘The clocks that time 
us’—circadian rhtyhms in neurodegerative disorders, Nat. Rev. Neurol. 10 (2014) 
683-693. 
[126] E.S. Musiek, D.M. Holtzman, Mechanisms linking circadian clocks, sleep, and 
neurodegeneration, Science 354 (2016) 1004-1008. 
[127] J. Mattis, A. Sehgal, Circadian rhythms, sleep, and disorders of aging. Trens. 
Endocrinol, Metab. 27 (2016) 192-203. 
[128] A. Sfera, K. Bullock, A. Price, L. Inderias, C. Osorio, Ferrosenescence: The iron 
age of neurodegeneration? Mech. Ageing Dev. (2017) pii: S0047-6374(17)30227-0. 
doi: 10.1016/j.mad.2017.11.012. 
 
 
Fig. 1. Protection of dopaminergic neurons from oxidative stress. A, Tyrosine 
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dehydrogenase is the key enzyme for dopamine synthesis from tyrosine. Dopaminergic 
neurons are highly susceptible to oxidative stress as dopamine can be metabolized to 
produce reactive quinones. Both GSTM2 and NQO1/DT-diaphorase are required to 
effectively detoxify quinones to protect the neurons [16]. The dopamine metabolite 
neuromelanin protects neurons. B, BDNF regulates metabolism in neurons and 
coordinates metabolic interactions between neurons and astrocytes. Astrocytes interact 
with neurons and support their survival and activity in various ways. Circadian rhythm 
controls daily changes of BDNF-TrkB signaling pathways in astrocytes thereby 
managing phase-dependent interaction between astrocytes and neurons.  
 
Fig. 2. NGF- and BDNF-mediated activation of Nrf2 and circadian rhythm. A, 
Stimulation of BDNF through full length receptor TrkB.FL with the tyrosine kinase 
domain suppresses p75
NTR
-mediated ceramide generation and does not activate Nrf2. 
Truncated receptor TrkB.T1 without tyrosine kinase domain can activate Nrf2 via the 
BDNF-TrkB.T1-p75
NTR
-ceramide-CK2 signaling pathway [31,76]. NGF has a higher 
affinity than BDNF for p75
NTR
 and can stimulate p75
NTR
-ceramide-CK2-Nrf2 signaling 
pathway. As Nrf2 can upregulate NGF gene expression, a positive feedback loop 
between Nrf2 and NGF can be formed. B, The transcription factor complex 
Clock-Bmal1 regulates expression of Per2, p75
NTR
, Rev-erbα and others. Per2 
suppresses the activity of the Clock-Bmal1 forming a negative feedback loop to make a 
daily rhythm. Rev-erbα represses expression of tyrosine hydroxylase which partly 
affects the daily rhythm of dopamine release [69].  
 
Fig. 3. Differences in BDNF-mediated signaling pathways in astrocytes and 
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neurons. A, Astrocytes predominantly express TrkB.T1 and 
BDNF-TrkB.T1-p75
NTR
-ceramide mediated signaling is strong in light/rest phase 
increasing mitochondrial activity backed by CK2-Nrf2 activation. Ceramide also 
activates protein phosphatase-1 (PP1) which facilitates glycogen synthesis. During the 
late light/rest to early dark/active phase, p75
NTR
 levels are expected to be decreased like 
Per2, while increased BDNF-TrkB.T1-A2AR-mediated signaling activates cAMP/PKA 
axis which suppresses mitochondrial activity and increases glycogen hydrolysis [31]. B, 
As neurons express both TrkB.FL and TrkB.T1, the signaling pathways differ from 
those in astrocytes. Notably, BDNF-TrkB.FL-p75
NTR
 signaling inhibits ceramide 
generation and induces temporal internalization of p75
NTR
 in CD63-positive 
multivesicular bodies (MVBs) for exosomes [74]. Therefore, BDNF may not efficiently 
activate Nrf2 in neurons via BDNF-TrkB.T1-p75
NTR
 signaling. But, local activation of 
ceramide-PP1 signaling in periphery may play a role in transport of cargos along axons 
in neurons.  
 
Fig. 4. BDNF secretion and processing in cultured hippocampal neurons and 
astrocytes. 
A, Activated hippocampal neurons secrete proBDNF (marked by ❶). Plasmin cleaves 
proBDNF to generate BDNF. Tissue-type plasminogen activator (tPA) is required to 
produce plasmin from plasminogen. Plasminogen activator inhibitor-1 (PAI-1) 
suppresses tPA activity. Astrocytes absorb proBDNF through p75
NTR
 and processed to 
generate mature BDNF within cells. Stimulation of astrocytes with ATP or with high K
+
 
releases mature BDNF (marked by ❷). B, Various stimulations open pannexin 1 
channels in astrocytes and secrete ATP (see Table 2). Extracellular ATP stimulates 
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P2X7R leading to induction of membrane trafficking to secrete mature BDNF and 
membrane microparticles including exosomes. 
 
Fig. 5. Daily increase in plasma glucocorticoids leads to opening Pannexin 1 
hemichannels and promotes interaction between astrocytes and neurons. A, 
Secretion of adrenal stress hormone glucocorticoids (GCs) is under the strict control of 
the master clock and HPA neuroendocrine axis. GC/corticosterone in plasma peaks (~50 
ng/mL) just before the initiation of dark/active phase in mice [123]. GC activates its 
receptor (GCR) which modulates expression of a wide variety of genes. A notable target 
of GCs-GCR is serum- and glucocorticoid-induced protein kinase-1 (Sgk-1), which 
mobilizes calcium signaling leading to opening pannexin 1 hemichannels in astrocytes. 
The peak of released ATP in the cerebrospinal fluid is about 0.5 nmol/mg protein [123]. 
B, We propose that systematic material transfer from astrocytes to neurons occur via 
microparticles and exosomes during the phase change from the light/rest to dark/active 
phase. Released BDNF from astrocytes and intercellular transfer of materials facilitate 
rapid metabolic changes in both cells, resulting in protection of neurons against 
oxidative damage and in increase in nursing activity of astrocytes. 
 
Table 1. Differential Nrf2-ARE regulated genes in astrocytes and neurons.  
 
Increased transcripts in astrocytes 
(total 97 genes) 
Increased transcripts in neurons 
(total 48 genes) 
Glucose metabolism: Glucose phosphate 
isomerase, Glyceraldehyde-3-phosphate DH, 
Enolase, Aconitase 2, Glucose transporter 1, 
Glucose-6-phosphate dehydrogenase, Glucan 
branching enzyme 1, etc. 
Mitochondria related:  
Mt creatine kinase,  
NADH dehydrogenase (Ndufa1),  
S100 calcium binding protein A1. 
Others:  
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GSH metabolism: GSTs (α4, mu 1, mu 3, pi 2, 
microsomal), Glutamate-cysteine-ligase. 
Antioxidants and others: Peroxiredoxin 1 & 6, 
Thioredoxin reductase 1, Catalase, NQO1, 
Ferritin light/heavy chain, 
Aldehyde dehydrogenase, 
Sequestosome-1 (p62/A170/ZIP), etc. 
Glucose phosphate isomerase 1,  
GSTs (α2, mu 1),  
Vascular cell adhesion molecule,  
Synaptotagmin 4, 
GABA-A receptor, etc. 
 
 
Compiled from supplemental Tables 2 and 3 in Kraft et al.[33]. The authors prepared 
fresh astrocytes and neurons from brain of mouse embryos and stimulated with 10 μM 
tBHQ for 24 h, then mRNAs were analyzed.  
 
 
 
Table 2. Stimulations that open pannexin 1 channels in astrocytes. 
 
Agents or conditions Mechanisms References 
High potassium  High K
+ 
induces a shift of activation 
potentials to more physiological range 
[89], [90] 
Interaction with neurons αvβ3 integrin (astrocytes) and Thy-1 
(neuron) interaction 
[107] 
Glucocorticoids Corticosterone activates SGK-1 in mice 
astrocytes 
[121] 
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Highlight 
● Astrocytes protect neurons from ferroptosis-like death 
● BDNF-TrkB.T1-p75NTR axis activates Nrf2 in astrocytes 
● Astrocytes transfer antioxidants to neurons via exosomes 
● Pannexin 1-P2X7R axis in astrocytes facilitates secretion of exosomes and BDNF  
● Glucocorticoids open pannexin 1 channels releasing ATP from astrocytes 
 
 
 
 
 
